Summary
The drugs used in migraine therapy can be divided into two groups: agents that abort an established migraine attack and agents used prophylactically to reduce the number of migraine attacks. Both groups have drugs that are specific for migrainous headaches and that are non-specific, and are used to treat the accompanying headache (analgesics), vomiting (anti-emetics), anxiety (sedatives and anxiolytics), or depression (antidepressants). The main drugs with specific action on migraine include ergot alkaloids (ergotamine, dihydroergotamine), agonists (sumatriptan) or partial agonists (methysergide) at a specific subtype of 5-HT1-like receptors, β-adrenoceptor antagonists (propranolol, metoprolol), calcium antagonists (flunarizine) and anti-inflammatory agents (indomethacin). The pharmacological basis of therapeutic action of several of these drugs is not well understood. In the case of the ergot alkaloids and 5-HT1-like receptor agonists, however, it is likely that the antimigraine effect is related to the potent and rather selective constriction of the large arteries and arteriovenous anastomoses in the scalp and dural regions. In addition, these drugs inhibit plasma extravasation into the dura in response to trigeminal ganglion stimulation, but it is possible that this effect is related to the selective vasoconstriction in the extracerebral vascular bed. The selectivity of the pharmacological effects of these antimigraine drugs (constriction of the extracerebral arteries and arteriovenous anastomoses, poor penetration into the central nervous system and the absence of an antinociceptive effect even after intrathecal administration) strongly suggests that excessive dilatation in the extracerebral cranial vasculature, probably initiated by a neuronal event, is an integral part of the pathophysiology of migraine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aellig WH (1983) Influence of pizotifen and ergotamine on the vasoconstrictor effect of 5-hydroxytryptamine and noradrenaline in man. Eur J Clin Pharmacol 25:759–762
Albers GW, Simon LT, Hamik A, Peroutka SJ (1989) Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache 29:215–218
Amano T, Meyer JS (1982) Cerebrovascular changes in patients with headache during antiserotonergic treatment. Headache 22:249–255
Ansell E, Fazzone T, Festenstein R, Johnson ES, Thavalpalan M, Wilkinson M, Wozniak I (1988) Nimodipine in migraine prophylaxis. Cephalalgia 8:269–272
Bateman DN, Kahn C, Davies DS (1980) The pharmacokinetics of metoclopramide in man. J Clin Pharmacol 9:371–377
Behan PO (1980) Prophylactic migraine therapy. J Drug Res 5 (suppl):53–57
Blau JN (ed) (1987) Migraine, clinical, therapeutic, conceptual and research aspects. Chapman and Hall, London
Bom AH, Heiligers JPC, Saxena PR, Verdouw PD (1989) Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors. Br J Pharmacol 97:383–390
Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576
Brand J, Hadoke M, Perrin VL (1987) Placebo-controlled study of a selective 5-HT1-like agonist, AH25086B, in relief of acute migraine. Cephalalgia 7 (suppl 6):402–403
Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Domperidone. A review on its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24:360–400
Buzzi MG, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202–206
Dallas FAA, Dixon CM, McCulloch RJ, Saynor DA (1989) The kinetics of 14C-GR43175 in rat and dog. Cephalalgia 9 (suppl 9):53–56
Den Boer MO, Villalòn CM, Heiligers JPC, Saxena PR, Humphrey PPA (1990) The craniovascular effects of sumatriptan. Br J Pharmacol 99:37P
Den Boer MO, Villalòn CM, Heiligers JPC, Humphrey PPA, Saxena PR (1991) Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol (in press)
Diamond S, Kudrow L, Stevens J, Shapiro DB (1982) Long-term study of propranolol in the treatment of migraine. Headache 22:268–271
Doenicke A, Siegel E, Hadoke A, Perrin VL (1987) Initial clinical study of AH25086B, in relief of acute migraine. Cephalalgia 7 (suppl 6):402–403
Feniuk W, Humphrey PPA, Perren MJ (1989) The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br J Pharmacol 96:83–90
Forssman B, Lindblad CJ, Zbornikova V (1983) Atenolol for migraine prophylaxis. Headache 23:188–190
Gelmers HJ (1985) Calcium-channel blockers in the treatment of migraine. Am J Cardiol 55:139B-143B
Glover V, Sandler M (1989) Can the vascular and neurogenic theories of migraine finally be reconciled? Trends Pharmacol Sci 10:1–3
Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC (1983) Metoclopramide. An up-dated view of its pharmacological properties and clinical use. Drugs 25:451–494
Headache Classification Committee, International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8 (suppl 7):10–73
Hedman C, Andersen AR, Andersson PG, Gilhus NG, Kangasniemi P, Olsson JE, Strandman E, Nestvold K, Olesen J (1988) Symptoms of classic migraine attacks: modifications brought about by metoprolol. Cephalalgia 8:279–284
Heyck H (1969) Pathogenesis of migraine. Res Clin Stud Headache 2:1–28
Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates IH, Butina D (1988) GR43175, a selective agonist for the 5-HT1-like receptor in the dog saphenous vein. Br J Pharmacol 94:1123–1132
Humphrey PPA, Perren MJ, Feniuk W, Connor HE, Oxford AW (1989) The pharmacology of a novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 9 (suppl 9):23–33
Humphrey PPA, Apperly E, Feniuk W, Perren MJ (1990) A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds) Cardiovascular pharmacology of 5-hydroxytryptamine, prospective therapeutic applications. Kluwer, Dordrecht, pp 417–428
Ibraheem JJ, Paalzow L, Tfelt-Hansen P (1983) Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 16:695–699
Kerber CW, Newton TH (1973) The macro- and microvasculature of the dura mater. Neuroradiology 6:175–179
Louis P, Spierings EL (1982) Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Cephalalgia 2:197–203
Lucking CH, Oestreich W, Schmidt R, Soyka D (1988) Flunarizine vs propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalalgia 8 (suppl 8):21–26
McArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ (1989) Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology 39:284–286
Müller-Schweinitzer E (1986) Serotonergic receptors in brain vessels. In: Owman C, Hardebo JE (eds) Neural regulation of brain circulation. Elsevier, Amsterdam, pp 219–234
Müller-Schweinitzer E, Weidmann H (1978) Basic pharmacological properties. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Handbook of experimental pharmacology. Springer, Berlin pp 87–232
Nielsen TH, Tfelt-Hansen P (1989) Lack of effect of GR43175 on peripheral arteries in man. Cephalalgia 9 (suppl 9):93–95
Parsons AA, Whalley ET (1989) Characterization of the 5-hydroxytryptamine receptor which mediates contraction of the human isolated basilar artery. Cephalalgia 9 (suppl 9):47–51
Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 16:687–699
Perren MJ, Feniuk W, Humphrey PPA (1989) The selective closure of feline arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 9 (suppl 9):41–46
Perrin VL, Färkkilä M, Goasguen J, Doenicke A, Brand J, Tfelt-Hansen P (1989) Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia 9 (suppl 9):63–72
Puzich R, Girke W, Heidrich H, Rischke M (1983) Dopplersonographische Untersuchungen der extrakraniellen Hirngefäse bei Migräne-Patienten nach Gabe von Ergotamintartrat. Dtsch Med Wochenschr 108:457–461
Rall TW, Schleifer LS (1985) Oxytocin, prostaglandins, ergot alkaloids and other drugs; toxicolytic agents. In: Goodman-Gilman A, Goodman LS, Rall TW, Murat F (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 926–945
Rowbotham GF, Little E (1965) New concepts on the aetiology and vascularization of meningiomata: the mechanism of migraine; the chemical process of cerebrospinal fluid; and the formation of collections of blood or fluid in the subdural space. Br J Surg 52:21–24
Ryan RE, Jr, Ryan RE (1975) Clonidine — its use in migraine therapy. Headache 14:190–192
Saito K, Markowitz S, Moskowitz MA (1988) Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 24:732–737
Saxena PR (1972) The effects of antimigraine drugs on the vascular responses by 5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: possible pharmacological implications to their antimigraine action. Headache 12:44–54
Saxena PR (1974) Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect. Eur J Pharmacol 27:99–105
Saxena PR (1987) Arteriovenous anastomoses and veins in migraine research. In: Blau JN (ed) Migraine, clinical, therapeutic, conceptual and research aspects. Chapman and Hall, London, pp 581–596
Saxena PR (1990) Is there still a case for the shunt hypothesis in migraine? In: Sandler M, Collins G (eds) Migraine, a spectrum of ideas. Oxford Medical Publications, Oxford, pp 191–197
Saxena PR (1990) 5-HT receptors and migraine. In: Sandler M, Collins G (eds) Migraine, a spectrum of ideas. Oxford Medical Publications, Oxford, pp 162–190
Saxena PR, de Vlaam-Schluter GM (1974) Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine. Studies in an experimental model for migraine. Headache 13:142–163
Saxena PR, Ferrari MD (1989) 5-HT1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 10:200–204
Saxena PR, Verdouw PD (1982) Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous blood flow. J Physiol 332:501–520
Saxena PR, Verdouw PD (1984) Effects of methysergide and 5-hydroxytryptamine (5-HT) on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors. Br J Pharmacol 82:817–826
Saxena PR, Verdouw PD (1985) Tissue blood flow and arteriovenous shunting in pigs measured with microspheres of four different sizes. Pflügers Arch 403:128–135
Saxena PR, van Houwelingen P, Bonta IL (1971) The effect of mianserin hydrochloride on the vascular responses to 5-hydroxytryptamine and related substances. Eur J Pharmacol 13:295–305
Saxena PR, Duncker DJ, Bom AH, Heiligers JPC, Verdouw PD (1986) Effects of MDL 72222 and methiothepin on carotid vascular responses to 5-hydroxytryptamine in the pig: evidence for the presence of “5-hydroxytryptamine1-like” receptors. Naunyn Schmiedebergs Arch Pharmacol 333:198–204
Saxena PR, Bom AH, Verdouw PD (1989) Characterization of 5-hydroxytryptamine receptors in the cranial vasculature. Cephalalgia 9 (suppl 9):15–22
Schamhardt HC, Verdouw PD, Van der Hoek TM, Saxena PR (1979) Regional myocardial perfusion and wall thickness and arteriovenous shunting after ergotamine administration to pigs with a fixed coronary stenosis. J Cardiovasc Pharmacol 1:673–686
Shanks RG (1985) Mechanism of action of beta-adrenoceptor antagonists in migraine. In: Carroll JD, Pfaffenrath V, Sjaastad O (eds) Migraine and beta-blockade. Hässle, Mölndal, pp 45–53
Sjaastad O, Dale I (1976) A new (?) clinical headache entity; “chronic paroxysmal hemicrania”. Acta Neurol Scand 54:140–159
Sjaastad O, Spierings ELH (1984) Hemicrania continua: another headache absolutely responsive to indomethacin. Cephalalgia 4:65–70
Solomon GD (1989) Verapamil in migraine prophylaxis — a five year review. Headache 29:425–427
Speight TM, Avery TM (1972) Pizotifen (BC 105): a review on its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 3:159–203
Stellar S, Ahrers SP, Meibohm AR, Reines SA (1984) Migraine prevention with timolol: a double crossover study. J Am Med Assoc 252:2576–2580
Stensrud P, Sjaastad O (1980) Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache 20:204–207
Tfelt-Hansen P, Nielsen TH (1990) Treatment of migraine with drugs related to 5-hydroxytryptamine. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds) Cardiovascular pharmacology of 5-hydroxytryptamine, prospective therapeutic applications. Kluwer, Dordrecht, pp 433–441
Tfelt-Hansen P, Standnes B, Kangasniemi P, Hakkarainen H, Olesen J (1984) Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 69:1–8
Tfelt-Hansen P, Brand J, Dano P, Doenicke A, Findley LJ, Iversen HK, Melchart D, Sahlender HM (1989) Early clinical experience with subcutaneous GR43175 in acute migraine: an overview. Cephalalgia 9 (suppl 9):73–77
Weerasuriya K, Patel L, Turner P (1982) Beta-adrenoceptor blockade and migraine. Cephalalgia 2:33–45
Wilkinson M (1980) The treatment of migraine. J Drug Res 5 (suppl):44–52
Zaimis E, Hanington E (1969) A possible pharmacological approach to migraine. Lancet II:298–300
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saxena, P.R., Den Boer, M.O. Pharmacology of antimigraine drugs. J Neurol 238 (Suppl 1), S28–S35 (1991). https://doi.org/10.1007/BF01642903
Issue Date:
DOI: https://doi.org/10.1007/BF01642903